The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. To achieve this, we will develop Idorsia into one of Europe’s leading biopharmaceutical companies, with a strong scientific core. We have identified five key strategic priorities to ensure the company’s success over the next 5 years.

  1. Deliver at least three products to market
  2. Build a commercial organization
  3. Bring Idorsia to profitability in a sustainable manner
  4. Create a pipeline with a sales potential of CHF 5 billion
  5. Utilize state-of-the-art technologies

Promising compounds

1. Idorsia aims to deliver at least three products to market with the potential to significantly change treatment options in their target disease, resulting in assets with major commercial potential.

We have a diversified and balanced clinical development pipeline covering multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.

We bring new perspectives to the development of innovative compounds, challenging accepted paradigms to answer the questions that matter to patients. Our key assets have the potential to transform treatment in the target indications.

From bench to bedside

2. Idorsia aims to build a commercial organization to maximize the value of our innovations.

A long-term strategic perspective is vital to ensure that our drugs address important healthcare challenges. A smart company must adopt creative approaches to delivering its medicines to patients.

To maximize the benefit of our pioneering therapies for patients, we will consider strategic partnerships and build our own commercial infrastructure to provide access to our drugs in certain therapeutic fields.

Becoming a sustainable company

3. Idorsia’s highly qualified professionals aim to rapidly advance the development pipeline and commercial readiness, so as to bring Idorsia to profitability within 5 years.

We are building Idorsia with a long-term focus and ambitious aspirations. We will run the company in a responsible and sustainable way. Becoming profitable will provide us with financial independence and secure our future.

Idorsia has the potential to generate significant revenues from product sales once the first of its pipeline candidates has received regulatory approval for commercialization. In the meantime, Idorsia has generated revenue through a milestone payment from its collaboration with Janssen on the co-development and commercialization of aprocitentan; this collaboration could also generate royalty payments. Furthermore, Idorsia could benefit from revenue-sharing payments relating to potential sales of ponesimod.

We are providing a supportive and stimulating environment for high-performing teams, recognizing and rewarding their contributions.

Building a bright future

4. Idorsia aims to create a clinical development pipeline of assets with a sales potential of at least
CHF 5 billion.

Idorsia is a high-potential biopharmaceutical company with a balanced portfolio of innovative drugs. As our assets advance and reach the market, there is a need to constantly replenish the pipeline with innovative compounds. This is where our highly productive drug discovery engine creates opportunities.

We are passionate and curious scientists, determined to help patients function better, feel better and live longer. Our drug discovery focuses on creating small molecules that are active on well-selected molecular targets. Knowledge built through the development of drugs active on one target can often benefit projects in several therapeutic areas.

Our focus on disorders with a high medical need means that our discoveries create significant value for patients, payors and society in general.

Mastering complexity without bureaucracy

5. Idorsia aims to increasingly utilize state-of-the-art technologies to aid discovery, development and commercialization of our innovative therapies.

As we want to remain at the cutting edge of science, it is vital that we consider innovative approaches from bench to bedside. We must integrate computational tools and digital technologies at different stages of the drug discovery, development and commercialization process, to maximize our potential and bring breakthrough medicines to patients.

Idorsia will look for creative ways to harness advances in technology to focus on novel targets and use new drug development methods. All functions of Pharmaceutical Development are streamlined to ensure the delivery of technically tailored and high-quality medicines. As the company establishes its commercial infrastructure, we will look for opportunities to use technology to benefit as many patients as possible.

When it comes to our colleagues’ daily life at Idorsia, we also employ pragmatic solutions to minimize the need for bureaucracy. Continuous learning and work-life balance are important engagement drivers to ensure that everyone thrives at Idorsia.

>> We are scientists at heart - I want to have people who have an obsession to hunt for drugs.

Jean-Paul Clozel

Chief Executive Officer

>> Each day we aim for more. We keep improving and continue learning.

Martine Clozel

Chief Scientific Officer

>> We are passionate about pragmatic science that translates into benefits for patients.

Guy Braunstein

Head of Global Clinical Development

>> All our activities have one common goal: finding the best solution.

André Muller

Chief Financial Officer